Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navitoclax and Abiraterone in mCRPC
NCT01828476Phase 2Terminated
- Sponsor
- Rutgers University
- Start
- Jun 2013
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of navitoclax in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Rutgers University. Started Jun 2013; status: terminated.
02
Drugs
navitoclax
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01828476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01828476.